Response rates by treatments received in the ts-AML cohort (grouped by age)
| Parameter . | High intensity . | Intermediate intensity . | Low intensity . | P . |
|---|---|---|---|---|
| Age <60 y | ||||
| N, evaluable | 31 | 7 | 9 | |
| CR | 6 (19) | 2 (29) | 1 (11) | .67 |
| CRp | 2 (6) | 1 (14) | 0 (0) | .51 |
| CR/CRp | 8 (26) | 3 (43) | 1 (11) | .2 |
| 4-wk mortality | 3 (10) | 1 (14) | 1 (11) | .93 |
| 8-wk mortality | 11 (35) | 1 (14) | 2 (22) | .46 |
| Age ≥60 y | ||||
| N, evaluable | 31 | 11 | 134 | |
| CR | 6 (19) | 3 (27) | 20 (15) | .47 |
| CRp | 4 (13) | 0 (0) | 10 (7) | .35 |
| CR/CRp | 10 (32) | 3 (27) | 30 (22) | .46 |
| 4-wk mortality | 1 (3) | 1 (9) | 10 (7) | .67 |
| 8-wk mortality | 10 (32) | 4 (36) | 25 (19) | .11 |
| Parameter . | High intensity . | Intermediate intensity . | Low intensity . | P . |
|---|---|---|---|---|
| Age <60 y | ||||
| N, evaluable | 31 | 7 | 9 | |
| CR | 6 (19) | 2 (29) | 1 (11) | .67 |
| CRp | 2 (6) | 1 (14) | 0 (0) | .51 |
| CR/CRp | 8 (26) | 3 (43) | 1 (11) | .2 |
| 4-wk mortality | 3 (10) | 1 (14) | 1 (11) | .93 |
| 8-wk mortality | 11 (35) | 1 (14) | 2 (22) | .46 |
| Age ≥60 y | ||||
| N, evaluable | 31 | 11 | 134 | |
| CR | 6 (19) | 3 (27) | 20 (15) | .47 |
| CRp | 4 (13) | 0 (0) | 10 (7) | .35 |
| CR/CRp | 10 (32) | 3 (27) | 30 (22) | .46 |
| 4-wk mortality | 1 (3) | 1 (9) | 10 (7) | .67 |
| 8-wk mortality | 10 (32) | 4 (36) | 25 (19) | .11 |
Data presented as no. (%).